ArticleJournal of endocrinological investigation2026
The association of GNAS defects with pro-inflammatory adipokine levels in pseudohypoparathyroidism type 1.
Article in Journal of endocrinological investigation, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
purposePseudohypoparathyroidism type 1 (PHP1), caused by GNAS defects, is associated with metabolic syndrome components like obesity and insulin resistance, potentially involving adipokine dysregulation. This study characterized serum adipokine profiles in PHP1 and elucidated the independent and interactive effects of GNAS defects and obesity.
methodsThis single-center, cross-sectional study included 60 PHP1 patients with molecularly confirmed GNAS defects (epigenetic or genetic). Controls (n = 60) were matched for body mass index (BMI), age, and sex. Serum adipokines were measured using multiplex enzyme-linked immunosorbent assay. Generalized linear models assessed independent/joint effects of GNAS defects and obesity on adipokines, adjusting for confounders.
resultsOverweight/obesity (OW/OB) prevalence was 58.3% among these PHP1 patients, significantly higher in PHP1A (90.9%, n = 11) vs. PHP1B (51.0%, n = 49; P = 0.037). Compared to controls, PHP1 patients exhibited significantly higher monocyte chemoattractant protein-1 (MCP-1) (P = 0.001), resistin (P = 0.001), chemerin (P < 0.001), adipsin (P = 0.007), and advanced glycation end-product receptor (AGER) (P = 0.014), but lower interleukin-8 (IL-8) (P < 0.001). After adjusting for age, sex, OW/OB, calcium, and parathyroid hormone, GNAS defects still independently increased resistin (mean difference [MD] = 0.76 ng/mL, P = 0.034), chemerin (geometric mean ratio [GMR] = 1.15, P = 0.008), and MCP-1 (GMR = 1.21, P = 0.043), but decreased IL-8 (GMR = 0.50, P = 0.004). Within PHP1 patients, resistin was higher in OW/OB individuals vs. non-OW/OB individuals (MD = 1.22 ng/mL, P = 0.005). Interaction analysis showed additive independent effects of GNAS defects and obesity on resistin level (P interaction=0.446).
conclusionGNAS defects are associated with aberrant pro-inflammatory adipokine secretion (resistin, chemerin, MCP-1, IL-8) in PHP1 patients independently of obesity. Obesity appears to amplify metabolic dysregulation, particularly reflected by increased resistin levels. These findings support the importance of early metabolic risk assessment and potential targeted interventions in PHP1.
Indexed as
Identifiers
41591732What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.